-
Mashup Score: 7FDA Adds Boxed Warning to Denosumab for Increased Risk of Hypocalcemia in Patients With CKD - 3 month(s) ago
According to the FDA review, patients with CKD receiving denosumab for osteoporosis who are on dialysis or have CKD-MBD are at the highest risk of severe hypocalcemia.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 9Efficacy and Safety of Aldosterone Synthase Inhibition With and Without Empagliflozin for Chronic Kidney Disease - American College of Cardiology - 4 month(s) ago
Amit Saha, MD
Source: www.acc.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 5CKD of Unknown Etiology: Is Taiwan Another Hotspot? - 4 month(s) ago
Author links open overlay panel Isabelle Dominique Tomacruz Amante 1, Ming-Yen Lin 2, Shang-Jyh Hwang 2 3
Source: www.sciencedirect.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 0Low baseline eGFR may increase risk for adverse drug reactions in patients with CKD - 4 month(s) ago
Lower baseline eGFR was identified as a major risk factor for adverse drug reactions in patients with chronic kidney disease, according to a recently published data.“Patients with chronic kidney disease have complex clinical presentations, take multiple medications and often receive inappropriate prescriptions,” Solène M. Laville, PharmD, PhD, and colleagues wrote. “Using data
Source: www.healio.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 158Cardiac metabolic remodelling in chronic kidney disease - Nature Reviews Nephrology - 4 month(s) ago
Chronic kidney disease is associated with an increased risk of cardiovascular disease, such as heart failure. Here, the authors examine myocardial metabolic remodelling in chronic kidney disease, including changes in energy substrate use, mitochondrial dysfunction and the role of cardiotonic steroids, and discuss potential metabolic therapies.
Source: www.nature.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 56Differences in the epidemiology, management and outcomes of kidney disease in men and women - 4 month(s) ago
Nature Reviews Nephrology – Improved understanding of kidney disease from a sex- and gender-specific perspective is needed to improve patient care. Here, the authors discuss differences in the…
Source: www.nature.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 0
The new model outperformed existing measures of CKD progression based on longitudinal eGFR data alone and saw further improvements in AUROC with the inclusion of additional clinical variables.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Association Between Urinary Biomarkers and CKD in Extremely Low Gestational Age Neonates - 5 month(s) ago
Children born <28 weeks gestation are at increased risk of chronic kidney disease (CKD). Urine biomarkers may shed light on mechanistic pathways and improve the ability to forecast CKD. We evaluated whether urinary biomarkers in neonates of low gestational age are associated with a reduced estimated glomerular filtration rate (eGFR) over time.
Source: www.ajkd.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 4Methotrexate Carries Higher Risk for Older CKD Patients - 5 month(s) ago
Adverse event data showed an increased risk of myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Association Between Urinary Biomarkers and CKD in Extremely Low Gestational Age Neonates - 6 month(s) ago
Children born <28 weeks gestation are at increased risk of chronic kidney disease (CKD). Urine biomarkers may shed light on mechanistic pathways and improve the ability to forecast CKD. We evaluated whether urinary biomarkers in neonates of low gestational age are associated with a reduced estimated glomerular filtration rate (eGFR) over time.
Source: www.ajkd.orgCategories: General Medicine News, NephrologyTweet
The FDA has determined that denosumab (Prolia; Amgen), which is used to treat osteoporosis, increases the risk of severe hypocalcemia in patients with advanced chronic kidney disease (#CKD), especially for patients who are undergoing dialysis. Read More: https://t.co/JS8cWWvTFz